TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06454409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05645549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centering Pregnancy with Care Navigation
Description: Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
Study: NCT04808193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will fill in the survey
Study: NCT06088836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retrolaminar block group
Description: Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group.
Description: Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles
Study: NCT04855071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ablative radiofrequency application
Description: Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual intervention
Description: The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual intervention
Description: The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
Study: NCT05485883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Lenvatinib
Description: Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Study: NCT04485260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: administered by mouth
Study: NCT06454409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT04485260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: administered by mouth
Study: NCT06454409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04764344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron
Study: NCT06508359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
Study: NCT04527419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematically mediastinal lymph node dissection
Description: Systematically mediastinal lymph node dissection will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No mediastinal lymph node dissection
Description: No mediastinal lymph node dissection will be performed.
Study: NCT04893499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chios mastic water
Description: Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo water
Description: Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chios mastic fruit juice
Description: Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fruit juice
Description: Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Study: NCT05986903

Intervention type: DRUG
Intervention: Tumor necrosis factor (TNF)-alpha inhibitors
Description: Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml.

Intervention type: DRUG
Intervention: Tumor necrosis factor (TNF)-alpha inhibitors
Description: Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml.
Study: NCT05661045

Intervention type: PROCEDURE
Intervention: low-flow anesthesia
Description: Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
Study: NCT06507839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THRV-1268
Description: THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THRV-1268
Description: THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Study: NCT06419387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Therapy Mobile App
Description: Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education Videos
Description: Psycho-education Videos include guidelines for increasing emotion regulation skills.
Study: NCT05446402

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Geologie Acne Regimen - one side of face
Description: Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)
Study: NCT06507839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THRV-1268
Description: THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05446402

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Proactive Acne Regimen - other side of face
Description: ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)
Study: NCT06233994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
Study: NCT06237803

Intervention type: OTHER
Intervention: storage of biological samples
Description: collect and store biological samples
Study: NCT06036953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
Study: NCT04199819

Intervention type: DRUG
Group type: OTHER
Intervention: entecavir
Description: Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
Study: NCT04807803

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Minimal hepatic encephalopathy (MHE)
Description: Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
Study: NCT06172920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients are receiving tramadol hydrochloride under thoracic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldolan
Description: Patients are receiving meperidine under thoracic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Patients are receiving Morphine hydrochloride under thoracic surgery
Study: NCT04905355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
Study: NCT05086055

Intervention type: BEHAVIORAL
Intervention: Kinematic movement analysis
Description: moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.

Intervention type: BEHAVIORAL
Intervention: Kinematic movement analysis
Description: moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
Study: NCT06384664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atricure's crysoSPHERE probe
Description: Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
Study: NCT06473935

Intervention type: OTHER
Intervention: Questionnaires and focus groups
Description: Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes.
Study: NCT06257836

Intervention type: OTHER
Intervention: MPFL-reconstruction
Description: Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
Study: NCT05577546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moor S brace treatment
Description: The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moor S brace treatment
Description: The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Three-Dimensional Scoliosis Exercise Treatment
Description: Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
Study: NCT04797949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: Women will be prescribed 81 mg of aspirin to take daily during pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
Study: NCT05718258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT05979857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-3164
Description: SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-3164
Description: SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
Study: NCT05219669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride
Description: 30 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride
Description: 30 mg/mL solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride
Description: 30 mg/mL solution
Study: NCT05429073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo volume-matching RGLS8429 dose
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo volume-matching RGLS8429 dose
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo volume-matching RGLS8429 dose
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo volume-matching RGLS8429 dose
Description: solution for subcutaneous injection
Study: NCT04528433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical-education-community Collaborated Intervention
Description: The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.